Indivior Q1 Earnings Call Highlights

Indivior (NASDAQ:INDV) reported first-quarter 2026 results showing beardown maturation successful U.S. SUBLOCADE and sharply higher profitability, portion besides outlining changes to its pipeline and detailing superior allocation actions taken during the quarter.

Q1 results driven by SUBLOCADE maturation and operating leverage

Total nett gross roseate 19% year-over-year to $317 million, which Chief Executive Officer Joe Ciaffoni said was “primarily driven by beardown U.S. SUBLOCADE performance.” Total SUBLOCADE nett gross accrued 32% year-over-year to $232 million, including U.S. SUBLOCADE nett gross of $218 million, up 33% versus the anterior twelvemonth period, according to Chief Financial Officer Ryan Preblick.

→ Palantir Is Down 30%: Noise? Or a Signal to Accumulate?

Indivior generated Adjusted EBITDA of $164 million, up 112% year-over-year, with borderline improving by 23 percent points. Preblick said non-GAAP operating expenses fell 21% year-over-year to $116 million, driven by “reductions successful headcount, the restructuring of the R&D and aesculapian affairs organizations, and footprint consolidations” tied to Phase 1 of the company’s “Indivior Action Agenda.”

Commercial execution and DTC run highlighted arsenic maturation drivers

Chief Commercial Officer Patrick Barry said Indivior delivered grounds SUBLOCADE caller diligent starts of astir 31,800 successful the quarter, a 29% year-over-year increase. That brought full U.S. SUBLOCADE patients treated implicit the past 12 months to 191,600 arsenic of quarter-end.

→ Homebuilder Earnings: D.R. Horton Sticks Out arsenic Pulte & NVR Sales Tank

SUBLOCADE dispense portion maturation accrued 20% year-over-year successful Q1, and Barry said full class stock of U.S. long-acting injectables (LAIs) remained unchangeable astatine 76%. Ciaffoni said the “acceleration successful SUBLOCADE dispense portion maturation was driven by improved commercialized execution and the aboriginal impact” of the company’s direct-to-consumer campaign, Move Forward successful Recovery.

Barry pointed to maturation successful the prescriber basal arsenic a starring indicator, noting that progressive SUBLOCADE prescribers grew 19% year-over-year and healthcare professionals treating 5 oregon much patients grew 20% year-over-year. He besides described respective operational initiatives, including enhanced work agreements with specialty pharmacies and a absorption connected utilization of SUBLOCADE’s accelerated initiation label.

→ Did Qualcomm Just Put Apple successful Check?

On accelerated initiation, Barry said SUBLOCADE is “the lone monthly long-acting injectable with an denotation for accelerated initiation connected time 1 and a 2nd dosing arsenic aboriginal arsenic time 8.” He added that astir 9% of caller patients are receiving the accelerated 2nd dose and 23% of progressive HCPs person begun prescribing the 2nd dose successful enactment with the expanded label. In Q&A, Barry said reaching highest plasma levels earlier “is peculiarly important successful the epoch of synthetic opioids,” and that if patients stabilize early, “we judge that implicit time, that could assistance with persistency,” portion emphasizing the institution volition proceed to measure the relationship.